NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis $0.79 0.00 (0.00%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$0.79 +0.00 (+0.20%) As of 09/25/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Milestone Pharmaceuticals Stock (NASDAQ:MIST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MIST alerts:Sign Up Key Stats Today's Range$0.75▼$0.8250-Day Range$0.79▼$1.2752-Week Range$0.75▼$3.06Volume1.26 million shsAverage Volume1.46 million shsMarket Capitalization$98.16 millionP/E RatioN/ADividend YieldN/APrice Target$6.40Consensus RatingModerate Buy Company Overview Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for cardiovascular conditions. The company’s lead product is etripamil, a short-acting, non-dihydropyridine calcium channel blocker formulated as a self-administered nasal spray. Etripamil has been developed primarily for the rapid treatment of paroxysmal supraventricular tachycardia (PSVT), a form of abnormally fast heart rhythm that can begin and end suddenly. Milestone has also evaluated the therapy in other cardiovascular applications, including the potential treatment of angina and related conditions. Founded in 2012, Milestone is headquartered in Montreal, Quebec, and has conducted clinical development activities in North America. The company is led by Joseph Oliveto, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Milestone Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreMIST MarketRank™: Milestone Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 560th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMilestone Pharmaceuticals has a consensus price target of $6.40, representing about 711.8% upside from its current price of $0.79.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Milestone Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.53% of the float of Milestone Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 10.59, which indicates bearish sentiment.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 5.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.79 News SentimentMilestone Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Milestone Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest9 people have searched for MIST on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Milestone Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.03% of the stock of Milestone Pharmaceuticals is held by insiders.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIST Stock News HeadlinesMilestone Enrolls First Canadian Patient In Phase 3 For EtripamilSeptember 27 at 1:30 PM | rttnews.comMilestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVRSeptember 24, 2026 | globenewswire.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. | Awesomely (Ad)Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 21, 2026 | americanbankingnews.comMilestone Wins China Approval for Etripamil Nasal SpraySeptember 4, 2026 | theglobeandmail.comMilestone Wins NMPA Approval For Etripamil Nasal Spray In PSVTSeptember 3, 2026 | rttnews.comMilestone Gets China Approval For Etripamil Nasal SpraySeptember 3, 2026 | rttnews.comMilestone Pharmaceuticals Announces China NMPA Approval of Etripamil for PSVT, Triggering $2 Million Milestone PaymentSeptember 3, 2026 | quiverquant.comQSee More Headlines MIST Stock Analysis - Frequently Asked Questions How have MIST shares performed this year? Milestone Pharmaceuticals' stock was trading at $2.02 on January 1st, 2026. Since then, MIST shares have decreased by 61.0% and is now trading at $0.7884. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.02. The firm earned $0.56 million during the quarter, compared to the consensus estimate of $0.82 million. Read the conference call transcript. When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $82 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,500,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Top institutional shareholders of Milestone Pharmaceuticals include Guardian Wealth Advisors LLC NC (0.27%), Seven Fleet Capital Management LP (0.22%), Squarepoint Ops LLC (0.19%) and TRU Independence Asset Management 2 LLC (0.12%). Insiders that own company stock include Joseph Oliveto, Lorenz Muller, David Bharucha and Jeffrey Edward Nelson. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include OPKO Health (OPK), Corbus Pharmaceuticals (CRBP), Tilray Brands (TLRY), VBI Vaccines (VBIV), Aquestive Therapeutics (AQST). Company Calendar Last Earnings8/12/2026Today9/27/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, MIST's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MIST CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees38Year Founded2005Price Target and Rating Average Price Target for Milestone Pharmaceuticals$6.40 High Price Target$8.00 Low Price Target$3.00 Potential Upside/Downside+711.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.06 million Net MarginsN/A Pretax Margin-3,657.42% Return on Equity-288.33% Return on Assets-58.27% Debt Debt-to-Equity Ratio3.25 Current Ratio8.13 Quick Ratio7.92 Sales & Book Value Annual Sales$1.55 million Price / Sales63.33 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book2.02Miscellaneous Outstanding Shares124,500,000Free Float118,236,000Market Cap$98.16 million OptionableOptionable Beta0.98 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:MIST) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersArizona Gold Explorer Nears First-Ever Resource EstimateA little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...Wall Street Logic | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIST Stock Alerts